Streetbeat News

Price Targets

JBHT

Benchmark analyst Christopher Kuhn has reaffirmed a Buy rating on JB Hunt Transport Servs (NASDAQ:JBHT) and increased the price target from $200 to $210.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 5:00 pm

LSCC

Benchmark analyst David Williams has reaffirmed a Buy rating on Lattice Semiconductor (NASDAQ:LSCC) and increased the price target from $70 to $95, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:55 pm

LEA

Benchmark analyst Michael Ward has reaffirmed a Buy rating on Lear Corporation (NYSE:LEA) and increased the price target from $188 to $200.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:54 pm

JBI

Benchmark analyst Reuben Garner has reaffirmed a Buy rating on Janus Intl Gr (NYSE:JBI) and increased the price target from $17 to $22.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:52 pm

SLNO

Oppenheimer analyst Leland Gershell has maintained an Outperform rating on Soleno Therapeutics (NASDAQ:SLNO) and increased the price target from $44 to $47.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:49 pm

LMNR

Roth MKM analyst Gerry Sweeney has reaffirmed a Buy rating on Limoneira (NASDAQ:LMNR) and increased the price target from $17 to $23.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:41 pm

ASGN

Truist Securities analyst Tobey Sommer has reaffirmed a Buy rating on ASGN Incorporated (NYSE:ASGN) and increased the price target from $93 to $110.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:28 pm

IMAX

B. Riley Securities analyst Eric Wold has maintained a Buy rating on Imax Corporation (NYSE:IMAX) but has reduced the price target from $27 to $21.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:26 pm

MRNA

Oppenheimer analyst Hartaj Singh upgraded Moderna Inc (NASDAQ:MRNA) to Outperform with a price target of $142, citing the company's potential to become a 'five-product commercial company' by 2026. Singh highlighted the expected approvals of Moderna's RSV vaccine (mRNA-1345), influenza vaccine (mRNA-1010), and INT (mRNA-4157), which could utilize the Accelerated Approval pathway. Despite a decline in COVID-19 vaccine sales, there's been an uptick in hospitalizations. Singh anticipates a decrease in OPEX for 2024 and 2025, with sales picking up in 2025. Moderna's shares were up 13.5% to $112.88 following the upgrade.

Portfolio Pulse from Priya Nigam

January 02, 2024 | 4:21 pm

AMC

B. Riley Securities analyst Eric Wold has maintained a Neutral rating on AMC Entertainment Holdings (NYSE:AMC) but has lowered the price target from $15 to $12.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 4:19 pm